We have recently developed the 225Ac-labeled minigastrin analog 225Ac-PP-F11N, which targets overexpressed cholecystokinin B receptor (CCKBR) in various human cancers including medullary thyroid, ovarian, and small-cell lung cancer, as well as gliomas (6). This evidence concerns the gene CCKBR and central nervous system cancer.